Publications

Type
Date
Drug Discovery
2019-06
Pharmacokinetic and Toxicokinetic Studies of a Sustained Release Liposomal Formulation of Dexamethasone Sodium Phosphate (TLC599) Following Intra-articular Injection in Dogs
Author(s) Tzung-Ju Wu, Wan-Ni. Yu, Ming-Ju Wu, Po-Chun Chang, Hui-Ting Wang and Sheue-Fang Shih; Taiwan Liposome Company, Taipei, Taiwan
Published European Congress of Rheumatology (EULAR 2019)
Drug Discovery
2019-05
Cartilage Damage and Synovial Toxicokinetic Study of a Sustained Release Liposomal Formulation of Dexamethasone Sodium Phosphate (TLC599) following Intra-articular Injection in Healthy Dogs and Rabbits
Author(s) W-N. Yu, M-J Wu, P-C Chang, S-F Shih; Taiwan Liposome Company, Taipei, Taiwan
Published 2019 OARSI World Congress on Osteoarthritis
Drug Discovery
2019-05
Single Intra-articular Injection of TLC599 Provided Sustained Pain Relief through 24 Weeks in Participants with Symptomatic Knee Osteoarthritis
Author(s) D. Hunter, C-C. Chang, J-C. Wei, H-Y. Lin, C. Brown, S-F. Shih; Univ. of Sydney, Sydney, Australia, Royal North Shore Hosp., Sydney, Australia, Div. of Allergy, Immunology and Rheumatology, Dept. of Internal Med., Sch. of Med., Coll. of Med., Taipei Med. Univ., Taipei, Taiwan, Div. of Allergy, Immunology and
Rheumatology, Chung Shan Med. Univ. Hosp., Taipei, Taiwan, Dept. of Internal Med., Cheng Hsin Gen. Hosp., Taipei,
Taiwan, Dept. of Allergy, Immunology and Rheumatology, Taipei Veterans Gen. Hosp., Taipei, Taiwan, Taiwan
Liposome Company, Taipei, Taiwan
Published 2019 OARSI World Congress on Osteoarthritis
Drug Discovery
2018-09
Safety, Tolerability, and Efficacy of a Novel Sustained-release Liposomal Formulation of Dexamethasone Sodium Phosphate (TLC599) in Patients with Knee Osteoarthritis
Author(s) Chien-Chih Lai, Chao-Ching Chiang, Chyou-Shen Lee, Chi-Ching Chang, Hsiao-Yi Lin, Tien-Ling Chen, and Sheue-Fang Shih
Published 20th Asia Pacific League of Associations for Rheumatology Congress
Oncology
Delivery Technology
2014-12
One-step Mixing with Humanized Anti-mPEG Bispecific Antibody Enhances Tumor Accumulation and Therapeutic Efficacy of mPEGylated Nanoparticles
Author(s) Kao C. H., Wang J. Y., Chuang K. H., Chuang C. H., Cheng T. C., Hsieh Y. C., Tseng Y. L., Chen B. M., Roffler S. R., Cheng T. L.
Published Biomaterials.
(37):9930-40, 2014.
Oncology
Clinical Development
2014-06
A Phase I Open-label, Sequential Dose-escalation Study Investigating the Safety, Tolerability, and Pharmacokinetics of Intravenous TLC388 Administered to Patients with Advanced Solid Tumors
Author(s) Ghamande, S., Lin, C. C., Cho, D. C., Shapiro, G. I., Kwak, E. L., Silverman, M. H., Tseng, Y. L., Kuo, M. W., Mach, W. B., Hsu, S. C., Coleman, T., Yang, J. C., Cheng, A. L., Ghalib, M. H., Chuadhary, I., Goel, S.
Published Invest New Drugs.
32(3):445-51, 2014.
Oncology
Non-Clinical Development
2013-11
Monitoring Tumor Response with [18F] FMAU in a Sarcoma-bearing Mouse Model after Liposomal Vinorelbine Treatment
Author(s) Chan P. C., Wu C. Y., Chang W. T., Lin C. Y., Tseng, Y. L., Liu R. S., Alauddin M. M., Lin W. J., Wang H. E.
Published Nucl Med Biol.
40(8):1035-42, 2013.
Oncology
Non-Clinical Development
Delivery Technology
2013-05
Tumor Burden Talks in Cancer Treatment with PEGylated Liposomal Drugs
Author(s) Lin Y. Y., Kao H. W., Li J. J., Hwang J. J., Tseng, Y. L., Lin W. J., Lin M. H., Ting G., Wang H. E.
Published PLoS One.
10;8(5):e63078, 2013.
Oncology
Clinical Development
2012-02
A Phase I Pharmacokinetic Study of Liposomal Vinorelbine in Patients with Advanced Solid Tumor
Author(s) Yang, S. H., Lin, C. C., Lin, Z. Z., Tseng, Y. L., and Hong, R. L.
Published Invest New Drugs,
30(1):282-289, 2012.
Oncology
Non-Clinical Development
Delivery Technology
2011-06
Pharmacokinetics and Dosimetry of (111) In/(188) Re-labeled PEGylated Liposomal Drugs in Two Colon Carcinoma-bearing Mouse Models
Author(s) Lin, Y. Y., Chang, C. H., Li, J. J., Stabin, M. G., Chang, Y. J., Chen, L. C., Lin, M. H., Tseng, Y. L., Lin, W. J., Lee, T. W., Ting, G., Chang, C. A., Chen, F. D., Wang, H. E.
Published Cancer Biother Radiopharm.,
26(3):373-380, 2011.
of
3
You are now leaving tlcbio.com

You have selected a link that will take you to a site maintained by a third party who is solely responsible for its contents.

TLC provides this link as a service to website visitors. TLC is not responsible for the privacy policy of any third party websites. We encourage you to read the privacy policy of every website you visit.

Click “Stay” or “X” to return to tlcbio.com or “Continue” to proceed.

Continue Stay